Physician
Stephen a Gephardt MD LTD
Stephen a Gephardt MD LTD was paid $1.03M by Medicaid between Aug 2022 and Dec 2024, across 15 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 66% of everything it billed.
33Billing provider infoSTEPHEN A GEPHARDT MD LTD
LAS VEGAS, NV 89113
LAS VEGAS, NV 89113
33aNPI1376925016assigned 06/18/2015
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$1.03M
24GClaims32,764
24DCodes billed15
24AFirst – last monthAug 2022 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Nevada
Rank by total paid#5 of 21
Median peer was paid$130K
This provider vs. median7.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 8,320 | $231K | |
| 2023 | 17,167 | $539K | |
| 2024incomplete | 7,277 | $264K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 66% | 14,444 | 12,583 | $686K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20% | 7,211 | 6,428 | $204K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.5% | 2,032 | 1,895 | $67K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 2,629 | 2,267 | $27K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.3% | 657 | 602 | $24K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 101 | 79 | $9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 198 | 169 | $5K |
| 64635 | <1% | 25 | 14 | $4K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,537 | 2,190 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,354 | 2,024 | $2K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 212 | 198 | $1K |
| 64636 | <1% | 25 | 14 | $965.95 |
3 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 56 | $783.71 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 264 | $466.54 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 19 | $30.46 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGEPHARDT, STEPHEN (MD/OWNER)